Ibrutinib Dosage Guide: Standard Doses for CLL, MCL, and WM

Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton's tyrosine kinase. It is used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia.

Ibrutinib Usual Adult Dosage

Chronic Lymphocytic Leukemia

420 mg orally once daily. Continue until disease progression or unacceptable toxicity.

Waldenström's Macroglobulinemia

420 mg orally once daily. Continue until disease progression or unacceptable toxicity.

Graft-Versus-Host Disease

420 mg orally once daily. Continue until progression of chronic graft-versus-host disease (cGVHD), recurrence of underlying malignancy, or unacceptable toxicity.

Ibrutinib Usual Pediatric Dosage

Usual Dosage for Graft-Versus-Host Disease

Children aged 1 year to less than 12 years: 240 mg orally once daily. Continue until chronic graft-versus-host disease (cGVHD) progression, recurrence of underlying malignancy, or unacceptable toxicity.

Graft-Versus-Host Disease Dosage Based on Body Surface Area (BSA)

(1) Oral Suspension

Dosage based on Body Surface Area (BSA) (to achieve 240 mg/m²):

BSA greater than 0.3 to 0.4 m²: 84 mg orally once daily.

BSA greater than 0.4 to 0.5 m²: 105 mg orally once daily.

BSA greater than 0.5 to 0.6 m²: 133 mg orally once daily.

BSA greater than 0.6 to 0.7 m²: 154 mg orally once daily.

BSA greater than 0.7 to 0.8 m²: 182 mg orally once daily.

BSA greater than 0.8 to 0.9 m²: 203 mg orally once daily.

BSA greater than 0.9 to 1 m²: 231 mg orally once daily.

BSA greater than 1 to 1.1 m²: 252 mg orally once daily.

BSA greater than 1.1 to 1.2 m²: 280 mg orally once daily.

BSA greater than 1.2 to 1.3 m²: 301 mg orally once daily.

BSA greater than 1.3 to 1.4 m²: 322 mg orally once daily.

BSA greater than 1.4 to 1.5 m²: 350 mg orally once daily.

BSA greater than 1.5 to 1.6 m²: 371 mg orally once daily.

BSA greater than 1.6 m²: 420 mg orally once daily.

(2) Capsules/Tablets

Dosage based on Body Surface Area (BSA) (to achieve 240 mg/m²):

BSA greater than 0.7 to 1 m²: 210 mg orally once daily.

BSA greater than 1 to 1.3 m²: 280 mg orally once daily.

BSA greater than 1.3 to 1.6 m²: 350 mg orally once daily.

BSA greater than 1.6 m²: 420 mg orally once daily.

Age 12 years and older: 420 mg orally once daily.

Ibrutinib Administration and Precautions

Administration Instructions

(1) Take at approximately the same time each day.

(2) Swallow capsules or tablets whole with a glass of water.

(3) Do not open, break, or chew capsules.

(4) Do not cut, crush, or chew tablets.

(5) Discard any remaining oral suspension 60 days after first opening the bottle.

(6) Avoid grapefruit, Seville oranges, and their products during treatment.

Monitoring Recommendations

(1) Cardiovascular: Assess cardiac history and function (at baseline); monitor for cardiac rhythm and function; monitor blood pressure.

(2) Hematology: Monitor for bleeding symptoms; perform complete blood count (CBC) monthly.

(3) Infection: Monitor for signs of infection and fever.

(4) Metabolic: Monitor for tumor lysis syndrome.

Diarrhea/Missed Dose Management

Diarrhea: Diarrhea may occur; contact doctor if diarrhea persists. Maintain adequate hydration.

Missed Dose: If a dose is missed, take it as soon as possible on the same day and resume the regular schedule the next day. Do not take an extra dose to make up for a missed dose.

Storage Requirements

Capsules: Store bottles at 20°C to 25°C; excursions permitted to 15°C to 30°C. Keep in original package until dispensing.

Oral Suspension: Store bottle at 2°C to 25°C; do not freeze. Dispense in original sealed container.

Tablets: Store in original package at 20°C to 25°C; brief excursions permitted to 15°C to 30°C.

Ibrutinib Dosage Adjustments in Special Populations

Dosage Adjustment for Renal Impairment

Mild and Moderate Renal Impairment (creatinine clearance > 25 mL/min): No dosage adjustment recommended.

Severe Renal Impairment (creatinine clearance < 25 mL/min): No data available.

Dosage Adjustment for Hepatic Impairment

(1) Adult Patients with B-Cell Malignancies

Mild Hepatic Impairment (Child-Pugh Class A): 140 mg orally once daily.

Moderate Hepatic Impairment (Child-Pugh Class B): 70 mg orally once daily.

Severe Hepatic Impairment (Child-Pugh Class C): Not recommended.

(2) Patients with Chronic Graft-Versus-Host Disease

Total bilirubin > 1.5 to 3 x ULN (unless non-hepatic or due to Gilbert's syndrome):

Patients 12 years and older: 140 mg orally once daily.

Patients 1 year to less than 12 years: 80 mg/m² orally once daily.

Total bilirubin > 3 x ULN (unless non-hepatic or due to Gilbert's syndrome): Not recommended.

Ibrutinib Dosage Adjustments for Adverse Reactions

Treatment with this product should be interrupted upon occurrence of adverse reactions. Once the adverse reaction has improved to Grade 1 or baseline level (recovery), follow the recommended dose adjustment schedule. Details should be followed according to physician's instructions.